SFA Therapeutics, Inc

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Some three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trial

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

SFA Therapeutics, Inc is developing novel small-molecule drugs derived from products in the human microbiome in an attempt to treat chronic inflammatory diseases and potentially cancer. The firm’s wo